HIF1A and glioblastoma: A specific signaling pathway between GSCs and microglia, the CLOCK-olfactomedin-like 3 (OLFML3)-HIF1α-legumain (LMGN)-cluster of differentiation 162 (CD162) axis, has been identified and serves as a potential therapeutic target for glioblastoma (Figure 2D) (80).